ATXI vs. ARAV, NBY, BPTS, ARDS, AGRX, CYCC, VRPX, CLVR, BPTSY, and PHIO
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Aravive (ARAV), NovaBay Pharmaceuticals (NBY), Biophytis (BPTS), Aridis Pharmaceuticals (ARDS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), Virpax Pharmaceuticals (VRPX), Clever Leaves (CLVR), Biophytis (BPTSY), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Aravive (NASDAQ:ARAV) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
Aravive presently has a consensus price target of $13.50, suggesting a potential upside of 33,565.84%. Given Avenue Therapeutics' higher probable upside, research analysts plainly believe Aravive is more favorable than Avenue Therapeutics.
Aravive has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.
Avenue Therapeutics has lower revenue, but higher earnings than Aravive. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
Avenue Therapeutics received 43 more outperform votes than Aravive when rated by MarketBeat users. However, 62.28% of users gave Aravive an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote.
Avenue Therapeutics has a net margin of 0.00% compared to Avenue Therapeutics' net margin of -569.65%.
In the previous week, Avenue Therapeutics had 31 more articles in the media than Aravive. MarketBeat recorded 31 mentions for Avenue Therapeutics and 0 mentions for Aravive. Avenue Therapeutics' average media sentiment score of 0.00 beat Aravive's score of -0.11 indicating that Aravive is being referred to more favorably in the media.
35.8% of Aravive shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Aravive beats Avenue Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
